Table 1 Demographic and clinical characteristics among proguanil/atovaquone users and matched comparisons
Proguanil/atovaquone users (N=16,817) | Non-users (N=168,170) | |||
|---|---|---|---|---|
No. | % | No. | % | |
Age at index | ||||
≤50 | 6642 | 39.5 | 66,420 | 39.5 |
51–60 | 4924 | 29.3 | 49,240 | 29.3 |
>60 | 5251 | 31.2 | 52,510 | 31.2 |
Sex | ||||
Males | 8196 | 48.7 | 81,960 | 48.7 |
Females | 8621 | 51.3 | 86,210 | 51.3 |
Birth country | ||||
Sweden | 16,449 | 97.8 | 163,114 | 97.0 |
Northern European country | 122 | 0.7 | 2045 | 1.2 |
Western European country | 50 | 0.3 | 489 | 0.3 |
Eastern European country | 68 | 0.4 | 1064 | 0.6 |
African country | 20 | 0.1 | 63 | 0.1 |
Middle-Eastern country | 50 | 0.3 | 784 | 0.5 |
Others | 58 | 0.4 | 611 | 0.3 |
Highest education level, year | ||||
1–9 | 1060 | 6.3 | 29,582 | 17.6 |
10–11 | 4808 | 28.6 | 78,241 | 46.5 |
≥12 | 10,949 | 65.1 | 60,347 | 35.9 |
Income | ||||
Lowest | 2839 | 16.9 | 44,167 | 26.3 |
Middle-low | 3521 | 20.9 | 47,135 | 28.0 |
Middle-high | 3551 | 21.1 | 38,168 | 22.7 |
Highest | 6906 | 41.1 | 38,700 | 23.0 |
IBD | ||||
No | 16,662 | 99.1 | 166,063 | 98.8 |
Yes | 155 | 0.9 | 2107 | 1.2 |
Obesity | ||||
No | 16,681 | 99.2 | 165,429 | 98.4 |
Yes | 136 | 0.8 | 2741 | 1.6 |
COPD | ||||
No | 15,956 | 94.9 | 158,059 | 94.0 |
Yes | 861 | 5.1 | 10,111 | 6.0 |
Colonoscopy | ||||
No | 16,199 | 96.3 | 162,277 | 96.5 |
Yes | 618 | 3.7 | 5893 | 3.5 |
CCI | ||||
0 | 14,686 | 87.3 | 140,683 | 83.7 |
1 | 1699 | 10.1 | 19,707 | 11.7 |
2 | 320 | 1.9 | 5053 | 3.0 |
≥3 | 112 | 0.7 | 2727 | 1.6 |
Outpatient visits, per year | ||||
0 | 9884 | 58.8 | 85,803 | 51.0 |
1 | 4959 | 29.5 | 48,408 | 28.8 |
2 | 1170 | 6.9 | 16,447 | 9.8 |
≥3 | 804 | 4.8 | 17,512 | 10.4 |
Prescription of other medicines | ||||
Aspirin | 1089 | 6.5 | 13,243 | 7.9 |
Statin | 1826 | 10.9 | 21,105 | 12.6 |